Full target enrollment of 216 patients achieved
Topline data from CARPO expected in 2Q 2024
LA JOLLA, Calif., April 24, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the last patient has been enrolled in its Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP). Auxora is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with acute inflammatory and immunologic illnesses.
"We are very grateful to the patients and families that have put their trust in us throughout this enrollment process," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "We are a significant step closer to delivering a potential treatment for acute pancreatitis, for which there is currently no approved therapy. We look forward to sharing the results of this clinical trial in the coming weeks once the last patient has finished treatment and the data have been analyzed."
CARPO is an international, randomized, double-blind, placebo-controlled, dose-ranging trial intended to establish Auxora's dose-response and efficacy in AP with accompanying systemic inflammatory response syndrome (SIRS). The trial reached its target enrollment of 216. These patients have been randomized into four groups to receive either 2.0 mg/kg, 1.0 mg/kg or 0.5 mg/kg of Auxora or a dose of placebo intravenously every 24 hours for a total of three doses. CARPO protocol requires that treatment and observation of patients continue for 30 days, and the company plans to report topline data later this quarter.